» Articles » PMID: 34386428

Identification of a Four Hypoxia-Associated Long Non-Coding RNA Signature and Establishment of a Nomogram Predicting Prognosis of Clear Cell Renal Cell Carcinoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Aug 13
PMID 34386428
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

To identify novel hypoxia-associated long non-coding RNAs (lncRNAs) as potential biomarkers, we developed a risk stratification signature and constructed a prognosis prediction nomogram of clear cell renal cell carcinoma (ccRCC). Hypoxia-related lncRNAs were identified through Pearson correlation analysis between the expression profiles of hypoxia-related differentially expressed genes and lncRNAs from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) dataset. Then, a signature of four key lncRNAs (, , , and ) was developed. The four lncRNAs were downregulated in high-grade, advanced stage, and high-risk ccRCC. The signature had an independent and long-standing prognosis prediction ability up to a 10-year follow-up. Notably, the risk score was significantly positively correlated with the infiltration abundances of six immune cells from the Tumor IMmune Estimation Resource (TIMER). The gene set enrichment analysis (GSEA) also suggested that the signature was involved in metabolism and tumorigenesis, which were closely related to the hypoxic tumor microenvironment. Ultimately, a nomogram of signature, age, stage, and grade, was built to predict the individual long-term survival possibility. Finally, the expressions of four lncRNAs were validated by quantitative real-time PCR (qRT-PCR). Our study identified a four-lncRNA signature and established a prognostic nomogram that reliably predicts survival in ccRCC. The findings may be beneficial to therapeutic customization and medical decision-making.

Citing Articles

Activation of RHO-GTPase gene pattern correlates with adverse clinical outcome and immune microenvironment in clear cell renal cell carcinoma.

Guo K, Ma P, Yang Q, Xu L, Zhang B, Zhang H Clin Exp Med. 2025; 25(1):67.

PMID: 39998699 PMC: 11861022. DOI: 10.1007/s10238-025-01593-3.


Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma.

Xu K, Li D, Ji K, Zhang Y, Zhang M, Zhou H Biol Direct. 2024; 19(1):71.

PMID: 39175011 PMC: 11340127. DOI: 10.1186/s13062-024-00517-7.


.

Wang S, Qi X, Liu D, Xie D, Jiang B, Wang J Comput Struct Biotechnol J. 2024; 23:491-505.

PMID: 38249783 PMC: 10796827. DOI: 10.1016/j.csbj.2023.12.016.


HAGLR, A Long Non-coding RNA of Potential Tumor Suppressive Function in Clear Cell Renal Cell Carcinoma: Diagnostic and Prognostic Implications.

Bardhan A, Banerjee A, Pal D, Ghosh A Mol Biotechnol. 2023; 66(12):3485-3497.

PMID: 37955777 DOI: 10.1007/s12033-023-00948-z.


Hypoxia-Related lncRNA Prognostic Model of Ovarian Cancer Based on Big Data Analysis.

Zhang Y, Zhang J, Wang F, Wang L J Oncol. 2023; 2023:6037121.

PMID: 37064863 PMC: 10104744. DOI: 10.1155/2023/6037121.


References
1.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

2.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

3.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

4.
Che J, Yao X, Wang C, Zheng J, Guo C . Hypoxia promoted renal cell carcinoma cell migration through regulating lncRNA-ENST00000574654.1. Am J Transl Res. 2020; 12(7):3884-3894. PMC: 7407743. View

5.
Muz B, de la Puente P, Azab F, Azab A . The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2016; 3:83-92. PMC: 5045092. DOI: 10.2147/HP.S93413. View